Publications by authors named "Anthony Shock"

Claim this Profile
M
Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology.
Marta Caballero-Ávila, Cinta Lleixà, Elba Pascual-Goñi, Lorena Martín-Aguilar, Núria Vidal-Fernandez, Anthony Shock

Neurol Neuroimmunol Neuroinflamm· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells .
Omar S Qureshi, Emma J Sutton, Rosemary F Bithell, Shauna M West, Rona M Cutler, Anthony Shock

MAbs· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune Encephalomyelitis.
Jana Remlinger, Adrian Madarasz, Kirsten Guse, Robert Hoepner, Maud Bagnoud, Anthony Shock

Neurol Neuroimmunol Neuroinflamm· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic.
Rocio Lledo-Garcia, Kate Dixon, Anthony Shock, Ruth Oliver

CPT Pharmacometrics Syst Pharmacol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita.
Ester Coutinho, Leslie Jacobson, Anthony Shock, Bryan Smith, Anthony Vernon

Neurol Neuroimmunol Neuroinflamm· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptors.
Anthony Shock, David Humphreys, Falk Nimmerjahn

J Allergy Clin Immunol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases.
Sijia Chen, Ross Paveley, Lianne Kraal, Lathees Sritharan, Elizabeth Stevens, Anthony Shock

J Autoimmun· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice.
Anika Kasprick, Maxi Hofrichter, Bryan Smith, Penelope Ward, Katja Bieber, Anthony Shock

Br J Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia.
Bryan Smith, Louis Christodoulou, Alison Clargo, Alison Eddleston, Kevin Greenslade, Anthony Shock

Int Immunopharmacol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Jacques-Eric Gottenberg, Thomas Dörner, Hendrika Bootsma, Valérie Devauchelle-Pensec, Simon J Bowman, Anthony Shock

Arthritis Rheumatol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Natalia V Giltiay, Geraldine L Shu, Anthony Shock, Edward A Clark

Arthritis Res Ther· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22.
Lamia Özgör, Carolin Brandl, Anthony Shock, Lars Nitschke

Eur J Immunol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor.
Simon Lumb, Sarah J Fleischer, Annika Wiedemann, Capucine Daridon, Alison Maloney, Anthony Shock

J Cell Commun Signal· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Thomas Dörner, Anthony Shock, David M Goldenberg, Peter E Lipsky

Autoimmun Rev· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
Anthony Shock, Linda Burkly, Ian Wakefield, Christopher Peters, Ellen Garber

Arthritis Res Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Vanessa Fleischer, Julia Sieber, Sarah J Fleischer, Anthony Shock, Guido Heine

Arthritis Res Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD22 and autoimmune disease.
Thomas Dörner, Anthony Shock, Kenneth G C Smith

Int Rev Immunol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry.
Matthew P Crump, Thomas A Ceska, Leo Spyracopoulos, Alistair Henry, Sarah C Archibald, Anthony Shock

Biochemistry· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.
John R Porter, Sarah C Archibald, Julien A Brown, Kirstie Childs, David Critchley, Anthony Shock

Bioorg Med Chem Lett· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammation.
Geoffrey John Bellingan, Ping Xu, Helen Cooksley, Helen Cauldwell, Anthony Shock

J Exp Med· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists.
John R Porter, Sarah C Archibald, Julien A Brown, Kirstie Childs, David Critchley, Anthony Shock

Bioorg Med Chem Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists.
John R Porter, Sarah C Archibald, Julien A Brown, Kirstie Childs, David Critchley, Anthony Shock

Bioorg Med Chem Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Squaric acid derivatives as VLA-4 integrin antagonists.
John R Porter, Sarah C Archibald, Kirstie Childs, David Critchley, John C Head, Anthony Shock

Bioorg Med Chem Lett· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis